Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses

In this week's View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF). He then explores the effect of race and sacubitril/valsartan use in HF patients documented in a pooled analysis of the PARADIGM-HF and PARAGON-HF trials. Finally, Dr. Eagle discusses the utility of systolic blood pressure (BP) polygenic risk scores and the treatment response in people with hypertension.    Subscribe to Eagle's Eye View  

There are no comments yet.

Please log in to write the first comment.